Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AP-GELP Study: Apremilast in Female Genital Erosive Lichen Planus
2017-004116-19Phase 2Completed
- Sponsor
- Oslo University Hospital
- Start
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in erosive lichen planus (ELP) comparing Apremilast with Placebo (2 arms). Primary endpoint: Primary endpoint: Mean GELP score at week 16 (apremilast vs placebo). Started Sep 2018; status: completed.
02
Drugs
apremilast
03
Conditions
erosive lichen planus (ELP)
Beyond the preview
Go deeper on 2017-004116-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004116-19.